Mission BioCapital is a VC firm making pivotal early-stage investments in biotech companies. We support companies with lab space, capital, and strategic partners; idea to exit.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2015
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B
Portfolio 64
| Date | Name | Website | Total Raised | Location |
| 10.01.2026 | EpiBiologi... | epibiologics.com | $157M | United Sta... |
| 15.11.2025 | Sensorium ... | sensorium.bio | - | - |
| 15.11.2025 | AI Protein... | aiproteins.bio | $18.2M | United Sta... |
| 20.05.2025 | Cavalry Bi... | cavalry.bio | - | United Sta... |
| 20.05.2025 | Progentos ... | progentos.com | $65M | - |
| 20.05.2025 | March Bio | march.bio | $33.2M | - |
| 30.01.2024 | TippingPoi... | tippingpointbiosciences.com | - | - |
| 30.01.2024 | Integrated... | integratedbiosciences.com | $17M | - |
| 10.01.2024 | Eikonizo T... | eikonizo.com | - | - |
| 15.03.2023 | Mediar The... | mediartx.com | $181M | United Sta... |
Show more
Mentions in press and media 23
| Date | Title | Description |
| 10.04.2026 | Nine Swiss startups recognized globally | Fast Company's annual ranking of the World's Most Innovative Companies identifies businesses setting the pace for global innovation across industries. This year's list includes two Swiss startups in category-leading positions. Axmed (found... |
| 11.01.2026 | Enodia Therapeutics Secures €20.7M Seed Funding to Pioneer Protein Degradation with AI | Enodia Therapeutics, a pioneering biotech firm, secured a significant €20.7 million ($25 million) seed funding round. This vital capital propels its innovative small-molecule platform, a breakthrough approach targeting protein degradation a... |
| 11.01.2026 | Enodia Therapeutics Raises €20.7M to Target "Undruggable" Proteins with SEC61 Platform | Enodia Therapeutics, a Paris-based biotech, has secured €20.7 million ($25 million) in seed funding. Argobio Studio launched the company. Enodia develops small molecules. Its platform targets protein degradation at the point of synthesis. I... |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | Enodia Therapeutics: €20.7 Million Seed Funding Closed To Advance SEC61-Based Small-Molecule Protein Degradation Platform | Enodia Therapeutics has raised €20.7 million (about $25 million) in a seed financing to advance a discovery platform that uses proteomics and machine learning to develop small molecules that degrade disease-driving proteins at the point of ... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 08.01.2026 | Enodia Therapeutics Raises €20.7M in Seed Funding | Enodia Therapeutics, a Paris, France-based biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, raised €20.7m (US$25m) in Seed financing. The round was co-led by Elaia, ... |
| 08.01.2026 | EpiBiologics Closes $107M Series B Funding | EpiBiologics, a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, raised $107M in Series B funding. The round was co-led by GV (Google Ventures) and Johnson & Johnson, through its corpo... |
| 18.11.2025 | Mission BioCapital closes on $143.75m for Fund VI | - |
| 29.08.2025 | Sensorium Therapeutics Raises $25M in Series A Funding | Sensorium’s current pipeline is powered by the company’s discovery platform SensAI™, which holistically integrates comprehensive biological data to identify compounds with a high probability of clinical success. Sensorium Therapeutics, a Bo... |
Show more